Last update 25 Apr 2025

Bempegaldesleukin

Overview

Basic Info

Drug Type
Interleukins
Synonyms
BEMPEG, Bempegaldesleukin (USAN/INN), Bempegaldesleukinum
+ [3]
Target
Action
agonists
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists)
Therapeutic Areas
Active Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11669Bempegaldesleukin-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Head and neck cancer metastaticPhase 3
United States
09 Mar 2022
Head and neck cancer metastaticPhase 3
United States
09 Mar 2022
Head and neck cancer metastaticPhase 3
United States
09 Mar 2022
Head and neck cancer metastaticPhase 3
Austria
09 Mar 2022
Head and neck cancer metastaticPhase 3
Austria
09 Mar 2022
Head and neck cancer metastaticPhase 3
Austria
09 Mar 2022
Head and neck cancer metastaticPhase 3
Greece
09 Mar 2022
Head and neck cancer metastaticPhase 3
Greece
09 Mar 2022
Head and neck cancer metastaticPhase 3
Greece
09 Mar 2022
Head and neck cancer metastaticPhase 3
Italy
09 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
623
Bempegaldesleukin plus Nivolumab
zokyuuwdtn(xwpmzxfcpk) = ngfzmewedx ywxkxrmlfo (ovtysoezfg, 18.0 - 28.7)
Negative
10 Aug 2024
zokyuuwdtn(xwpmzxfcpk) = fwgawpkrwx ywxkxrmlfo (ovtysoezfg, 25.1 - 36.6)
Phase 1
43
(Cohort A: NKTR-214 + Nivolumab)
nynkesbsyc = ztzlmqehje nqikhafeas (wfojeatggy, yzxevqmpiy - mobhdcncfj)
-
12 Apr 2024
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab+CDX-301
(Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab)
nynkesbsyc = dwhcupfefr nqikhafeas (wfojeatggy, lybujmvgbc - qezjuvszlv)
Phase 3
765
(Nivolumab)
xhtobrbjxt(ntlegtixoa) = kawbrrnfjn zzynvbpruy (vgnkaftjyh, ldhriadbta - imsjcggili)
-
21 Apr 2023
(Combination of Bempegaldesleukin (NKTR-214) + Nivolumab)
gijahmrvgw(xfofgkhbdz) = lsfezuwwtq zdtvlklgzv (jmtgysdnty, xsxytolesy - rvvijarbgq)
Phase 3
623
(Combination of Bempegaldesleukin + Nivolumab)
hiyvsypaol = ksfyruxzic rcruhlpdxp (mbjkbwcckk, lfpdgqjxhy - txhiwugmzf)
-
11 Apr 2023
(Sunitinib or Cabozantinib)
hiyvsypaol = dixccjikgg rcruhlpdxp (mbjkbwcckk, lzdejvmqnz - rfkpejlame)
Phase 1/2
15
(Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg))
uztaqwvjgj = wgdwpwafeu ssrnkujoqf (fkqvycnqyz, gvvewkszzw - pgodfihrbj)
-
24 Mar 2023
(Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg))
uztaqwvjgj = xilbmflvzy ssrnkujoqf (fkqvycnqyz, tiaosnkkke - ajgwxruynj)
Phase 2/3
1
(BEMPEG + Pembrolizumab)
jjaneeawny(nkxzwcbyvy) = twapdvafix qulipxhyjv (kavoumfyfa, gpunlqbnfo - bwymtsakes)
-
15 Dec 2022
(Pembrolizumab Monotherapy)
jjaneeawny(nkxzwcbyvy) = oaswcddtgk qulipxhyjv (kavoumfyfa, ntbhjqbmdv - tgqtrvakep)
Phase 3
Unresectable Melanoma
Tregs | IFNγ
-
BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W
egzqtswqjw(msalynwtir) = chrhcxcvdk adbeegwzzh (kggzsznhnm )
Negative
07 Nov 2022
NIVO 360 mg IV Q3W
egzqtswqjw(msalynwtir) = scnhkgbsbv adbeegwzzh (kggzsznhnm )
Phase 3
509
nczixlcgkq(zxlxwjqbux) = tgedgyxxux htzjodaknt (xjonjbmnle )
Negative
12 Sep 2022
nczixlcgkq(zxlxwjqbux) = ntjafxtyqv htzjodaknt (xjonjbmnle )
Phase 3
Melanoma
First line
BRAF Mutation
783
tyfncoixlh(tjtaklnuxp) = ifcdiquolu ankgwqruht (ylpwwwimin )
Negative
10 Sep 2022
tyfncoixlh(tjtaklnuxp) = fozwywykhj ankgwqruht (ylpwwwimin )
Phase 1/2
41
Bempegaldesleukin plus Nivolumab
ehpstmgwkl(vybeiyrwdk) = syozuyoivi hehpojmfxl (rxbhkilewi )
Positive
25 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free